NHS Drug Pricing Crisis: UK Officials Working to Resolve Row

Here’s a summary of​ the key points ⁢from the provided text,focusing on⁤ the UK’s pharmaceutical landscape:

*⁤ Drug Pricing Dispute: The UK government and major ‌pharmaceutical companies‍ (MSD,astrazeneca,Eli Lilly) have been in a dispute over drug pricing. Negotiations broke down in ⁢August after a hard line from Health ⁣Secretary Wes⁤ Streeting. Companies paused or abandoned UK investments as a​ result.
* UK as⁢ Unattractive Market: Eli Lilly’s CEO⁤ described the UK ⁣as “probably the worst country in Europe” for drug prices.
* Government ⁢Response: Ministers are‍ considering raising the cost-effectiveness thresholds for new medicines in the ⁤NHS by around 25% to make ‍the​ UK more attractive to pharma companies. They are actively trying to rebuild ‍the relationship with ⁤the industry.
* ⁢ External Pressures: donald ⁣Trump is pressuring pharmaceutical companies to lower US prices and increase investment/prices⁣ elsewhere, adding complexity to⁢ the situation.
* Signs of Investment: Despite​ the ‌dispute, there have been recent investments: Moderna (£150m vaccine⁤ site),⁢ BioNTech ⁢(£1bn over 10 ‍years), and Convatec (£500m research⁢ center).
* Ambition for Leadership: ⁢The‌ UK aims⁣ to become the leading life sciences ⁣power in Europe by 2030 and a top three global player by 2035.
* london’s ‌Strength: London’s‌ life⁢ sciences sector has⁢ attracted⁢ significant venture capital (£1.6bn this year), exceeding investment in Paris, Stockholm, and Berlin combined.
* ⁣ Ongoing Resolution: ​The⁣ government is ​”laser focused” on resolving the issues with pharmaceutical companies.

In​ essence, the⁢ UK ⁢is attempting to ‌balance affordable healthcare (through the NHS) with ​attracting ‍investment from the pharmaceutical industry, facing ⁢pressure from both domestic and international sources.